Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2017 May 3;16(8):1693–1704. doi: 10.1158/1535-7163.MCT-16-0821

Figure 2. MLN4924 rescues activity of the Lats Hippo pathway kinases and blocks cell cycle progression.

Figure 2

(A) The NF2-mutant mesothelioma line Meso-33 was treated with the indicated concentrations of MLN4924 for 24 hours and immunoblotted as indicated. (B) Meso-33 cells were transfected with control or DCAF1 siRNAs and subsequently treated for 16 hours with DMSO or the indicated concentrations of MLN4924 and lysed 72 hours post-transfection for immunoblotting as indicated. P-YAPS127/YAP fold change based on densitometric analysis is indicated. (C) Meso-33 cells were transfected with indicated siRNAs and harvested after 80 hours (left) or treated with the indicated concentrations of MLN4924 for 36 hours (right) for immunoblotting as indicated. (D) Meso-33 cells were treated with 0.5 μM MLN4924 for the indicated times and immunoblotted as indicated. (E) NF2-positive MPM lines and immortalized but untransformed mesothelial lines (Met5a and LP9) were treated with increasing doses of MLN4924 and subjected to MTT proliferation assay after 72 hours of treatment. Proliferation of MLN4924-treated cells was normalized to respective DMSO-treated controls. Error bars are ±SEM (n=3). (F) NF2-mutant MPM lines were treated as in (E).